{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:52Z","timestamp":1792801912821,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00262-022-03274-6","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T07:04:10Z","timestamp":1661238250000},"page":"775-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma"],"prefix":"10.1007","volume":"72","author":[{"given":"Guru P.","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Louis","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley Alexander","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao X.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Kilbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Thomas","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Caleb","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspreet S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Pico-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarina","family":"Gafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Perschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"3274_CR1","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602\u20134608","journal-title":"J Clin Oncol"},{"key":"3274_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191\u2013199. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571","journal-title":"J Clin Oncol"},{"key":"3274_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"key":"3274_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet"},{"key":"3274_CR5","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-19-0183","volume":"25","author":"ME Gatti-Mays","year":"2019","unstructured":"Gatti-Mays ME, Strauss J, Donahue RN et al (2019) A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. Clin Cancer Res 25:4933\u20134944. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0183","journal-title":"Clin Cancer Res"},{"key":"3274_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00262-016-1816-7","volume":"65","author":"SP Foy","year":"2016","unstructured":"Foy SP, Mandl SJ, de la Cruz T et al (2016) Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunol Immunother 65:537\u201349. https:\/\/doi.org\/10.1007\/s00262-016-1816-7","journal-title":"Cancer Immunol Immunother"},{"key":"3274_CR7","doi-asserted-by":"publisher","first-page":"e0150084","DOI":"10.1371\/journal.pone.0150084","volume":"11","author":"SP Foy","year":"2016","unstructured":"Foy SP, Sennino B, de la Cruz T et al (2016) Poxvirus-based active immunotherapy with PD-1 and LAG-3 dual immune checkpoint inhibition overcomes compensatory immune regulation, yielding complete tumor regression in mice. PLoS One 11:e0150084. https:\/\/doi.org\/10.1371\/journal.pone.0150084","journal-title":"PLoS One"},{"key":"3274_CR8","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/1097-0142(19821115)50:10<2052::aid-cncr2820501015>3.0.co;2-f","volume":"50","author":"G Jautzke","year":"1982","unstructured":"Jautzke G, Altenaehr E (1982) Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and its correlation with grading and staging on tissue sections of urinary bladder carcinomas. Cancer 50:2052\u20132056. https:\/\/doi.org\/10.1002\/1097-0142(19821115)50:10%3c2052::aid-cncr2820501015%3e3.0.co;2-f","journal-title":"Cancer"},{"key":"3274_CR9","first-page":"1195","volume":"1","author":"P Allard","year":"1995","unstructured":"Allard P, Fradet Y, Tetu B, Bernard P (1995) Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1:1195\u20131202","journal-title":"Clin Cancer Res"},{"key":"3274_CR10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/modpathol.3880220","volume":"13","author":"EM Genega","year":"2000","unstructured":"Genega EM, Hutchinson B, Reuter VE, Gaudin PB (2000) Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 13:1186\u20131191. https:\/\/doi.org\/10.1038\/modpathol.3880220","journal-title":"Mod Pathol"},{"key":"3274_CR11","first-page":"4945","volume":"7","author":"S Stojnev","year":"2014","unstructured":"Stojnev S, Ristic-Petrovic A, Velickovic LJ, Krstic M, Bogdanovic D, do Khanh T, Ristic A, Conic I, Stefanovic V (2014) Prognostic significance of mucin expression in urothelial bladder cancer. Int J Clin Exp Pathol 7:4945\u20134958","journal-title":"Int J Clin Exp Pathol"},{"key":"3274_CR12","doi-asserted-by":"publisher","first-page":"e92742","DOI":"10.1371\/journal.pone.0092742","volume":"9","author":"S Kaur","year":"2014","unstructured":"Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK (2014) Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis. PLoS One 9:e92742. https:\/\/doi.org\/10.1371\/journal.pone.0092742","journal-title":"PLoS One"},{"key":"3274_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1158\/1078-0432.CCR-04-1609","volume":"11","author":"KY Tsang","year":"2005","unstructured":"Tsang KY, Palena C, Yokokawa J et al (2005) Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res 11:1597\u20131607. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1609","journal-title":"Clin Cancer Res"},{"key":"3274_CR14","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1158\/1078-0432.CCR-11-0649","volume":"17","author":"M Mohebtash","year":"2011","unstructured":"Mohebtash M, Tsang KY, Madan RA et al (2011) A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17:7164\u20137173. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0649","journal-title":"Clin Cancer Res"},{"key":"3274_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","volume":"1","author":"CR Heery","year":"2015","unstructured":"Heery CR, Ibrahim NK, Arlen PM et al (2015) Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol 1:1087\u20131095. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2736","journal-title":"JAMA Oncol"},{"key":"3274_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ et al (2019) Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol 37:1051\u20131061. https:\/\/doi.org\/10.1200\/JCO.18.02031","journal-title":"J Clin Oncol"},{"key":"3274_CR17","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","volume":"14","author":"JL Gulley","year":"2008","unstructured":"Gulley JL, Arlen PM, Tsang KY et al (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14:3060\u20133069. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0126","journal-title":"Clin Cancer Res"},{"key":"3274_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"key":"3274_CR19","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"3274_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:28:02Z","timestamp":1677133682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3274"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03274-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Guru Sonpavde: Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics\/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Immunomedics\/Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly\/Loxo Oncology, Infinity Pharmaceuticals; Research Support to Institution: Sanofi, Astrazeneca, Immunomedics\/Gilead, QED, Predicine, BMS; Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid); Data safety monitoring committee: Mereo; Travel costs: BMS, Astrazeneca; Writing\/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)Benjamin Louis Maughan: Consulting or Advisory Role: Janssen Oncology, Exelixis, Tempus, Bristol Myers Squibb, Astellas Medivation, Bayer, AVEO, Clovis Oncology, Merck, Peloton Therapeutics; Research Funding: Clovis Oncology, Bristol Myers Squibb, Bavarian Nordic, Exelixis; Travel, Accommodations, Expenses: Exelixis Bradley Alexander McGregor: Consulting or Advisory Role: Bayer, Seattle Genetics\/Astellas, Exelixis, AstraZeneca, Astellas Pharma, Genentech\/Roche, Nextar, Janssen Oncology, Pfizer, EMD Serono, Eisai, Dendreon, Bristol Myers Squibb; Research Funding: Bristol Myers Squibb, Exelixis, Calithera Biosciences, Seattle Genetics\/Astellas Xiao X. Wei: : Advisory Board: Novartis. Research support to institution: BMS.Kerry L. Kilbridge: None Richard J. Lee: Consulting or Advisory Role - Bayer; Exelixis; Janssen Oncology; Noxopharm; Tolero Pharmaceuticals; Research Funding - Janssen Evan Y. Yu: Consulting\/Advisory: Abbview, Advanced Accelerator Applications, Bayer, Clovis, Exelixis, Janssen, Merck, Sanofi, Seagen; Research Support to Institution: Bayer, Blue Earth, Daiichi-Sankyo, Dendreon, Lantheus, Merck, Seagen, Taiho Michael Thomas Schweizer: paid consultant to AstraZeneca, PharmaIn, Janssen and Resverlogix; research funding to his institution from Zenith Epigenetics, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Madison Vaccines, Hoffman-La Roche, Tmunity and SignalOne Bio, Inc.Robert B. Montgomery: None Heather H. Cheng: Consulting or Advisory Role: AstraZeneca; Research Funding: Sanofi, Janssen, Clovis Oncology, Color Genomics Foundation, Fred Hutchinson Cancer Research Center Andrew Caleb Hsieh: In last 3 years - Sponsored Research: eFFECTOR, Inc Rohit Jain: Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; EMD Serono; Infinity Pharmaceuticals; Merck; Myovant Sciences; Pfizer; Pfizer\/Astellas; Propella Therapeutics; Tavanta Therapeutics; very; Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seattle Genetics (Inst)Petros Grivas: (in the last 3 years): Dr. Grivas has received consulting fees from AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb,, Dyania Health, EMD Serono, Exelixis,  Fresenius Kabi, Genentech\/Roche, Genzyme, Gilead Sciences, GlaxoSmithKline, Guardant Health,  Infinity Pharmaceuticals, Janssen, Lucence Health, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, UroGen. His institution has received grants from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics.Jaspreet S. Grewal: Employment - EMD Serono; Consulting or Advisory Role \u2013 Tempus; Research Funding - Bristol-Myers Squibb (Inst); Galera Therapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst)Cesar Pico-Navarro, Zarina Gafoor, Teresa Perschy: Employees of Bavarian-Nordic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}